Characterizing cancers by prevalence on the PD-L1/CD8 axis

被引：0
|
作者：
Schmidt, Guenter [1 ]
Steele, Keith [2 ]
Meier, Armin [1 ]
Herz, Thomas [1 ]
Tan, Tze Heng [1 ]
Higgs, Brandon [2 ]
Althammer, Sonja [1 ]
Huss, Ralf [1 ]
机构：
[1] Definiens AG, Munich, Germany
[2] MedImmune LLC, Gaithersburg, MD USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P83
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Halioseek™, a dual CD8 and PD-L1 IVD assay to improve NSCLC patients stratification
    Monville, Florence
    Prestat, Emmanuel
    Vanhille, Laurent
    Adam, Julien
    Coslet, Sergiu
    Lauge, Caroline
    Davin, Caroline
    Losch, Merle Sophie
    Batista, Luciana
    Fieschi, Jacques
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [32] Differential expression of PD-1/PD-L1 axis and CD4/CD8 ratio in mediastinal lymph nodes of patients with idiopathic pulmonary fibrosis and lung cancer
    Karampitsakos, Theodoros
    Chrysikos, Serafeim
    Vamvakaris, Ioannis
    Papaioannou, Ourania
    Bouros, Evangelos
    Tzilas, Vasilios
    Katsaras, Matthaios
    Dimakou, Katerina
    Manali, Effrosyni
    Papiris, Spyridon
    Bouros, Demosthenes
    Bakakos, Petros
    Tzouvelekis, Argyris
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [33] Significance of Immunotyping by CD8 and PD-L1 Immune Checkpoint Inhibitor in Epithelial Ovarian Carcinoma
    Srinivasan, Radhika
    Bansal, Akriti
    Rohilla, Manish
    Rai, Bhavana
    Rajwanshi, Arvind
    Suri, Vanita
    Saha, Subhas
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1137 - 1139
  • [34] Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer
    Aghajani, Marra Jai
    Yang, Tao
    Schmitz, Ulf
    James, Alexander
    McCafferty, Charles Eugenio
    de Souza, Paul
    Niles, Navin
    Roberts, Tara L.
    ENDOCRINE CONNECTIONS, 2020, 9 (10): : 1028 - 1041
  • [35] The prognostic value of CD8+infiltration and PD-L1 expression in salivary gland cancers
    Kesar, N.
    Winkelmann, R.
    Roedel, F.
    Oppermann, J.
    Balster, S.
    Ghanaati, S.
    Brandts, C.
    Martin, D.
    Roedel, C.
    Balermpas, P.
    Von der Gruen, J.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S1010 - S1010
  • [36] Hematologic Cancers Break Down a 'Checkpoint': Targeting the PD-1/PD-L1 Axis
    Timmerman, John
    ONCOLOGY-NEW YORK, 2015, 29 (06): : 440 - 441
  • [37] Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway
    Haspot, Fabienne
    Fehr, Thomas
    Gibbons, Carrie
    Zhao, Guiling
    Hogan, Timothy
    Honjo, Tasuku
    Freeman, Gordon J.
    Sykes, Megan
    BLOOD, 2008, 112 (05) : 2149 - 2155
  • [38] Prognostic impact of PD-1, PD-L1, and CD8 genes expression in peripheral blood in gastric cancer.
    Ito, Shuhei
    Masuda, Takaaki
    Fukagawa, Takeo
    Kouyama, Yuta
    Wakiyama, Hiroaki
    Yoshikawa, Yukihiro
    Noda, Miwa
    Kidogami, Shinya
    Hu, Qingjiang
    Sato, Kuniaki
    Nambara, Sho
    Saito, Tomoko
    Sakimura, Shotaro
    Hayashi, Naoki
    Kuroda, Yousuke
    Eguchi, Hidetoshi
    Sasako, Mitsuru
    Mimori, Koshi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Efficacy of anti-PD1/PD-L1 immunotherapy in non-small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status
    Galon, Jerome
    Bibeau, Frederic
    Greillier, Laurent
    Fumet, Jean David
    Ilie, Alis
    Monville, Florence
    Lauge, Caroline
    Catteau, Aurelie
    Boquet, Isabelle
    Majdi, Amine
    Oulkhouir, Youssef
    Brandone, Nicolas
    Adam, Julien
    Sbarrato, Thomas
    Kassambara, Alboukadel
    Fieschi, Jacques
    Garcia, Stephane
    Lepage, Anne Laure
    Tomasini, Pascale
    Ghiringhelli, Franc Commacis
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers
    Hou, Yanjun
    Nitta, Hiroaki
    Parwani, Anil, V
    Li, Zaibo
    HUMAN PATHOLOGY, 2019, 86 : 108 - 114
12345